Emcure Pharma posted 41% YoY PAT growth to ₹215 crore in Q1, with strong gains across domestic and global markets.

• Revenue rose 15.7% YoY to ₹2,101 crore, driven by domestic therapy growth and robust global performance.
• International sales grew 22%, led by 42% RoW growth and strong launches in Canada (16.4%) and Europe (12.8%).
• EBITDA grew 20.1% with 19.2% margins; strong product pipeline and Sanofi tie-up to drive future growth.